Skip to main content
Anke van den Berg
prof. dr.

I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.

The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth
Published in: Cancers
The expression of several microRNAs (miRNAs) is known to be changed in Burkitt lymphoma (BL), compared to its normal counterparts. Although for some miRNAs, a role in BL was demonstrated, for most of them, their function is unclear. In this study, we aimed to identify miRNAs that control BL cell growth. Two BL cell lines were infected with lentiviral pools containing either 58 miRNA inhibitors or 44 miRNA overexpression constructs. Eighteen constructs showed significant changes in abundance over time, indicating that they affected BL growth. The screening results...
Fubiao Niu, Marta Kazimierska, Ilja M Nolte, Miente Martijn Terpstra, Debora de Jong, Jasper Koerts, Tineke van der Sluis, Bea Rutgers, Ryan M O'Connell, Klaas Kok, Anke van den Berg, Agnieszka Dzikiewicz-Krawczyk, Joost Kluiver
Molecular imaging in lymphoma beyond F-18-FDG-PET: understanding the biology and its implications for diagnostics and therapy
Published in: Lancet Haematology
Mature lymphoproliferative diseases are a heterogeneous group of neoplasms arising from different stages of B-cell and T-cell development. With improved understanding of the molecular processes in lymphoma and novel treatment options, arises a growing need for the molecular characterisation of tumours. Molecular imaging with single-photon-emission CT and PET using specific radionuclide tracers can provide whole-body information to investigate cancer biology, to evaluate phenotypic heterogeneity, to identify resistance to targeted therapy, and to assess the biodistribution of drugs in patients. In this Review, we evaluate the existing literature on...
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles
Published in: JCO Precision Oncology
PURPOSE: Molecular tumor boards (MTBs) provide physicians with a treatment recommendation for complex tumor-specific genomic alterations. National and international consensus to reach a recommendation is lacking. In this article, we analyze the effectiveness of an MTB decision-making methodology for patients with non-small-cell lung cancer (NSCLC) with rare or complex mutational profiles as implemented in the University Medical Center Groningen (UMCG). METHODS: The UMCG-MTB comprises (pulmonary) oncologists, pathologists, clinical scientists in molecular pathology, and structural biologists. Recommendations are based on reported actionability of variants and molecular interpretation of pathways...
Analysis of Released Circulating Tumor Cells During Surgery for Non-Small Cell Lung Cancer: are they what they appear to be?
Published in: Clinical Cancer Research
Purpose: Tumor cells from patients with lung cancer are expelled from the primary tumor into the blood, but difficult to detect in the peripheral circulation. We studied the release of circulating tumor cells (CTCs) during surgery to test the hypothesis that CTC counts are influenced by hemodynamic changes (caused by surgical approach) and manipulation. Experimental Design: Patients undergoing video-assisted thoracic surgery (VATS) or open surgery for (suspected) primary lung cancer were included. Blood samples were taken before surgery (T0) from the radial artery (RA), from both the RA...
Menno Tamminga, Sanne de Wit, Caroline Van De Wauwer, Hilda van den Bos, Joost F Swennenhuis, Theo J Klinkenberg, T Jeroen N Hiltermann, Kiki C Andree, Diana C J Spierings, Peter M Lansdorp, Anke van den Berg, Wim Timens, Leon Wmm Terstappen, Harry Jm Groen
Cell-free DNA as biomarker in Hodgkin lymphoma patients
Published in: Klinische Pädiatrie
G. W. Tan, M. M. Terpstra, K. Kok, A. Diepstra, A. van den Berg, W. Plattel